Form 4 for PBYI PUMA BIOTECHNOLOGY, INC.
Accepted 2026-02-20 00:00:00 ET · period of report 2026-02-18 · accession 0001437749-26-004948 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-20 | 2026-02-18 | PBYI | AUERBACH ALAN H | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +159.8K | 7.31M | +2% | $0 |
| D | 2026-02-20 | 2026-02-18 | PBYI | AUERBACH ALAN H | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +227.5K | 227.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | A | A | 159,778 | $0.00 | 7,305,729 | D | — | — | (F1) Represents the grant of Restricted Stock Units ('RSUs"). Subject to the Reporting Person's continued status as an Employee of the Company, the RSUs shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-18 | A | A | 227,474 | $0.00 | 227,474 | D | $6.68 · — to 2036-02-17 | 227,474 Common Stock | (F2) Subject to the Reporting Person's continued status as an Employee of the Company, the Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares of Common Stock subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events. |